These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28727951)

  • 21. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
    Hope R; Chaudhry A; Adkin R; Livermore DM
    Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR; Smith CJ; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
    Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3999-4004. PubMed ID: 22508304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).
    Pfaller MA; Sader HS; Shortridge D; Castanheira M; Flamm RK; Mendes RE
    J Chemother; 2019 Jul; 31(4):188-194. PubMed ID: 31079589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
    Jones RN; Flamm RK; Castanheira M; Sader HS; Smart JI; Mendes RE
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):184-187. PubMed ID: 28377166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
    Jones RN; Sader HS; Flamm RK
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of telavancin against resistant gram-positive bacteria.
    Krause KM; Renelli M; Difuntorum S; Wu TX; Debabov DV; Benton BM
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2647-52. PubMed ID: 18443122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
    Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
    Pfaller MA; Jones RN; Doern GV; Sader HS; Kugler KC; Beach ML
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):283-97. PubMed ID: 10212756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3882-8. PubMed ID: 24777091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Morrissey I; Hawser S; Lob SH; Karlowsky JA; Bassetti M; Corey GR; Olesky M; Newman J; Fyfe C
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.